It takes approximately 1.3 Bi USD and a median 8.3 years to bring new drugs to market because approximately 97% of all drug candidates will fail during drug discovery and development. Supplementing or replacing clinical trials with virtual patients (i.e., digital representations of human disease biology, e.g., digital twins in medical devices) is a viable solution that is gaining market and regulatory support for example in rare diseases where few patients exist or in patient populations with ethical concerns such as young children or pregnant mothers. Douglas McCloskey earned his PhD in bioengineering from UC San Diego in 2017, receiving the Siebel Scholars Foundation grant for his work on metabolism and evolution. From 2018 to 2021, he was a principal investigator at the Technical University of Denmark, leading a team to automate the design-build-test-analyze cycle for developing cell factories and therapies. As Chief Scientific Officer and co-founder at AliveX Biotech (2021–2022), he led the creation of an AI and Omics systems immunology platform for drug discovery and patient stratification. Currently, he is a PI at BioMed X, partnering with Sanofi to develop a virtual patient model to predict drug efficacy. This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx